




# PHARMACEUTICAL 2023

Y-mAbs Therapeutics Inc.  
Rank 203 of 446





RealRate

# PHARMACEUTICAL 2023

## Y-mAbs Therapeutics Inc. Rank 203 of 446



The relative strengths and weaknesses of Y-mAbs Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Y-mAbs Therapeutics Inc. compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 46% points. The greatest weakness of Y-mAbs Therapeutics Inc. is the variable Expenses, reducing the Economic Capital Ratio by 50% points.

The company's Economic Capital Ratio, given in the ranking table, is 106%, being 63% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	130,447
Cost of Goods Sold	7,467
Intangible Assets	2,986
Liabilities, Current	28,284
Liabilities, Non-Current	1,701
Other Assets	7,419
Other Compr. Net Income	-40
Other Expenses	100
Other Liabilities	2,250
Other Net Income	-757
Other Revenues	65,267
Property and Equipment	604
Research and Development	91,572
Selling, General and Administrative Expense	60,939

Output Variable	Value in 1000 USD
Assets	141,456
Liabilities	32,235
Expenses	160,078
Revenues	65,267
Stockholders Equity	109,221
Net Income	-95,568
Comprehensive Net Income	-95,588
Economic Capital Ratio	106%